The delta-specific opioid glycopeptide bbi-11008: Cns penetration and behavioral analysis in a preclinical model of levodopa-induced dyskinesia

Mitchell J. Bartlett, Omar S. Mabrouk, Lajos Szabò, Andrew J. Flores, Kate L. Parent, Jean M. Bidlack, Michael L. Heien, Robert T. Kennedy, Robin Polt, Scott J. Sherman, Torsten Falk

Research output: Contribution to journalArticlepeer-review

Abstract

In previous work we evaluated an opioid glycopeptide with mixed µ/δ-opioid receptor agonism that was a congener of leu-enkephalin, MMP-2200. The glycopeptide analogue showed penetration of the blood–brain barrier (BBB) after systemic administration to rats, as well as profound central effects in models of Parkinson’s disease (PD) and levodopa (L-DOPA)-induced dyskinesia (LID). In the present study, we tested the glycopeptide BBI-11008 with selective δ-opioid receptor agonism, an analogue of deltorphin, a peptide secreted from the skin of frogs (genus Phyllomedusa). We tested BBI-11008 for BBB-penetration after intraperitoneal (i.p.) injection and evaluated effects in LID rats. BBI-11008 (10 mg/kg) demonstrated good CNS-penetrance as shown by microdialysis and mass spectrometric analysis, with peak concentration levels of 150 pM in the striatum. While BBI-11008 at both 10 and 20 mg/kg produced no effect on levodopa-induced limb, axial and oral (LAO) abnormal involuntary movements (AIMs), it reduced the levodopa-induced locomotor AIMs by 50% after systemic injection. The N-methyl-D-aspartate receptor antagonist MK-801 reduced levodopa-induced LAO AIMs, but worsened PD symptoms in this model. Co-administration of MMP-2200 had been shown prior to block the MK-801-induced pro-Parkinsonian activity. Interestingly, BBI-11008 was not able to block the pro-Parkinsonian effect of MK-801 in the LID model, further indicating that a balance of mu-and delta-opioid agonism is required for this modulation. In summary, this study illustrates another example of meaningful BBB-penetration of a glycopeptide analogue of a peptide to achieve a central behavioral effect, providing additional evidence for the glycosylation technique as a method to harness therapeutic potential of peptides.

Original languageEnglish (US)
Article number20
Pages (from-to)1-15
Number of pages15
JournalInternational journal of molecular sciences
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2021

Keywords

  • Basal ganglia
  • L-DOPA
  • Parkinson’s disease

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Fingerprint Dive into the research topics of 'The delta-specific opioid glycopeptide bbi-11008: Cns penetration and behavioral analysis in a preclinical model of levodopa-induced dyskinesia'. Together they form a unique fingerprint.

Cite this